论文部分内容阅读
目的探讨新辅助化疗治疗进展期胃癌的临床疗效及影响因素。方法选择进展期胃癌患者60例,随机分为治疗组和对照组,每组30例。对照组患者直接给予手术治疗,治疗组患者进行2个周期的新辅助化疗,随后进行手术治疗,观察两组患者并发症及术后生存率情况。结果治疗组患者根治切除术的比例明显高于对照组,姑息性切除术比例明显低于对照组,差异均有统计学意义(P<0.05)。ⅢA期和肿瘤<6cm的患者有效率高于ⅢB期和肿瘤≥6cm的患者有效率,但差异无统计学意义(P>0.05)。结论新辅助化疗治疗进展期胃癌是一个有效且副作用较小的方案,肿瘤分期及肿瘤大小可能是影响新辅助化疗的因素。
Objective To investigate the clinical effect and influencing factors of neoadjuvant chemotherapy for advanced gastric cancer. Methods Sixty patients with advanced gastric cancer were randomly divided into treatment group and control group, with 30 cases in each group. Patients in the control group were treated directly with neoadjuvant chemotherapy. Patients in the treatment group were treated with neoadjuvant chemotherapy for 2 cycles. Surgical treatment was subsequently performed to observe the complications and postoperative survival of the two groups. Results The proportion of radical resection in the treatment group was significantly higher than that in the control group. The proportion of palliative resection was significantly lower than that in the control group (P <0.05). The patients with stage ⅢA and tumor <6cm were more effective than those with stage ⅢB and tumor ≥6cm, but the difference was not statistically significant (P> 0.05). Conclusion Neoadjuvant chemotherapy for advanced gastric cancer is an effective and less side effects of the program, the tumor stage and tumor size may be the impact of neoadjuvant chemotherapy.